Indehaveren af markedsføringstilladelsen foreslog en udvikling af strategier, som kan identificere problemkilden og finde frem til en mere immunogen formel.
The MAH proposed the development of strategies to identify the source of the problem, as well as to produce a more immunogenic formulation.